The Schwab U.S. Dividend Equity ETF (SCHD) pulled in $679.26 million over five trading days as its share price climbed 2.39%, TipRanks reported.
Three of the fund’s biggest holdings made news in the same stretch, adding fresh fuel to a monthslong rotation out of growth and into defensive dividend payers. The March reconstitution had already reshaped what that money was buying.
Merck, Abbott, and Amgen powered the weekly surge
Merck’s partnership with Moderna on intismeran autogene, a personalized mRNA cancer vaccine, met its primary endpoint of recurrence-free survival in combination with Keytruda in the Phase 3 INTerpath-001 melanoma trial announced Aug. 19, 2026, according to Merck’s press release.
Moderna CEO Stéphane Bancel called the mRNA trial data a pivotal moment for personalized cancer therapy.
For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality.
Morgan Stanley upgraded Merck to Overweight from Equalweight and lifted its price target to $179 from $116, while UBS raised its target to $175 from $145 and Goldman Sachs raised its target to $160 from $140, both keeping Buy ratings, TipRanks reported on Aug. 20, 2026.
A settlement of infant-formula litigation also lifted the stock. Abbott is SCHD’s largest holding at about 4.78% of assets as of Aug. 13, 2026, according to TopDividendETFs.
Amgen launched its Phase 3 DeLLphi-315 trial testing a subcutaneous version of its lung-cancer drug tarlatamab and completed a Phase 1 study comparing two formulations of its cholesterol drug evolocumab, TipRanks confirmed.
The March reconstitution reshaped SCHD’s portfolio
The fund’s annual reconstitution took effect on March 23, 2026, adding 25 stocks and removing 22 from the Dow Jones U.S. Dividend 100 Index, the Motley Fool reported.
Major additions included UnitedHealth Group, Procter & Gamble, Qualcomm, and Accenture. Energy exposure dropped by roughly 8 percentage points, falling from about 21% to 13%, Seeking Alpha reported.
Healthcare rose 4 percentage points, and technology added 3. Tech weight climbed from 11% to more than 15% by early June, the Motley Fool reported at the time.
The March reconstitution improved SCHD’s quality screens, but the tech drift from 11% toward 15% before quarterly rebalancing pulled it back to 8.75% shows how quickly the fund’s risk character can shift between reconstitutions.
Healthcare at 21.05% and consumer staples at 19.32% still anchor the portfolio, according to TopDividendETFs, and together they represent more than 40% of the fund.
AFP Contributor / Getty Images
A stalled Fed kept the rotation running
SCHD has returned about 30.11% year to date through Aug. 21, 2026, outpacing the S&P 500’s 12.11% return by roughly 18 percentage points, 24/7 Wall St reported.
That reversed three years of underperformance from 2023 through 2025, HNGN noted. The federal funds rate sits at 3.50% to 3.75% after five consecutive holds through July 2026, Trading Economics data confirm.
Nine of the 18 officials who submitted projections supported at least one increase in the June dot plot, and Fed Chair Kevin Warsh did not submit a dot, according to the Fed’s June Summary of Economic Projections.
More Charles Schwab:
- Charles Schwab, Fidelity sound alarm on Roth IRA rule
- Morgan Stanley doubles down on Schwab after earnings
- Schwab plots S&P 500 prediction markets push with Cboe
Three members dissented at the July 29 meeting in favor of a hike. Futures markets priced a September rate increase at about 40% probability as of Aug. 12, 2026, Forbes reported.
MUFG projected the Fed staying on hold through the year-end, with easing pushed to early 2027.
SCHD’s trailing dividend yield of about 3.08% compares favorably with the Vanguard Dividend Appreciation ETF (VIG) at 1.69% and the iShares Core Dividend Growth ETF (DGRO) at 1.72%, according to Dividend Vision data as of July 22, 2026.
Its price-to-earnings ratio of about 19 also reflects a discount to the S&P 500, according to The Motley Fool, reinforcing the value case drawing billions into dividend strategies.
3 risks that could stall the SCHD rotation trade
The rotation isn’t guaranteed to hold. Three forces could reverse it.
- Megacap tech reclaiming leadership: An April 2026 tech rally briefly compressed SCHD’s relative gains, showing how quickly growth sentiment can shift the balance, the Motley Fool reported.
- Concentration risk from rebalancing: The March reconstitution briefly lifted tech to over 15% and put Qualcomm and Texas Instruments in the top two spots, the Motley Fool flagged in June. Since then, quarterly rebalancing has reversed that shift, tech is back to 8.75% as of Aug. 13, 2026.
- Yield compression versus Treasuries: SCHD’s trailing yield has fallen from about 3.60% at reconstitution to 3.09% as the price rallied. The 30-year Treasury now out-yields dividend stocks by 2.2 percentage points, the Motley Fool reported.
- Source: Motley Fool analysis of SCHD
SCHD’s strongest week signals a broader shift in investor positioning
The $679 million weekly inflow reflects a 2026 rotation into defensive dividend names, not an isolated spike. Healthcare and consumer staples at roughly 41% of the fund anchor the trade, while Merck, Abbott, and Amgen catalysts gave the latest push.
The rotation’s durability hinges on the Fed staying on hold, inflation not reaccelerating, and tech stocks not reasserting dominance.
What isn’t yet clear is how long dividend yields near 3% can hold investor attention when a 30-year Treasury pays over 5% risk-free, or whether the March reconstitution’s tighter quality screens will insulate SCHD if growth leadership snaps back.
Both questions get answered in the next few Fed meetings, not in the next few weeks of inflow data.
Related: Schwab SCHD holders are missing its ideal dividend ETF match
